From:  Innovations in hydrocephalus modeling: bridging animal models, bioengineering platforms, and precision therapies

 Comparative overview of hydrocephalus models.

Model typeFeatures & mechanismAdvantagesLimitationsReferences
Genetic animal modelsL1CAM, CCDC39, Rsph9, Foxj1, GemC1 mutantsDefine mechanisms, mimic congenital hydrocephalusSpecies-specific CSF dynamics, embryonic lethality, systemic abnormalities, and limited translation[1822, 24, 52, 54, 116]
Induced animal modelsKaolin injection, neuraminidase, intraventricular hemorrhageTemporal control, mimic secondary hydrocephalus, reproducibleVariable phenotypes, methodology-dependent, less suited for developmental studies[47, 61, 6567]
Large animal modelsPig, dog (natural or induced hydrocephalus)Closer ventricular size and CSF hydrodynamics to humansCostly, ethical concerns, and fewer genetic tools[43, 50, 68]
iPSC-derived organoidsPatient-derived, CRISPR-editedHuman genetic background, personalized modeling, and drug screeningLack of vascularization and CSF flow, heterogeneity, and scalability issues[35, 48, 49, 69, 70, 77]
AssembloidsFusion of brain + vascular or choroid plexus organoidsIntroduce barrier and vascular elements, model CSF interactionsEarly stage, structural heterogeneity, scalability challenges[41, 77, 134]
Bioengineered organ on chipSVZ-on-chip, CSF flow chipsDynamic CSF-like flow, biomechanical fidelity, human relevanceFabrication complexity, standardization, and regulatory challenges[36, 83, 84, 134, 135]

The table summarizes major experimental platforms, detailing their origin, mechanisms, advantages, disadvantages, and representative references. In addition to traditional genetic, induced, and large-animal models, it encompasses new ones such as organoids from iPSCs, assembloids, and organ-on-chip platforms reflecting the evolution of hydrocephalus research. CSF: cerebrospinal fluid; iPSC: induced pluripotent stem cell; SVZ: subventricular zone.